Get the app
US › Healthcare

OnKure Therapeutics, Inc. (OKUR)

US · Healthcare · Biotechnology

$2.96+2.78%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-15.3M
EPS
$-0.31
EPS estimate
$-0.58

EPS came in at -0.31 against a street estimate of -0.58 — a beat of 46.6%.

Key statistics

Market cap
$132.4M
Forward P/E
0.0
P/B
0.80
Book value
$4.25
EPS (TTM)
$-3.03
52-week high
$5.38
52-week low
$2.23
50-day MA
$4.04
200-day MA
$3.67

Analyst view

Analysts rate OnKure Therapeutics, Inc. a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $15.50.

Shareholding

Insiders
10.45%
Institutions
87.22%

Largest institutional holders

FundStake
RA Capital Management, LLC9.87%
StepStone Group LLC6.57%
ADAR1 Capital Management LLC6.01%
Bvf Inc4.89%
Vivo Capital, LLC4.76%
Vestal Point Capital LP4.54%
Trails Edge Capital Partners, LP3.55%
Adage Capital Partners Gp LLC2.98%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for OnKure Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.